Anti-inflammatory and bacteriostatic oral liquid containing lactic acid bacteria and preparation method of anti-inflammatory and bacteriostatic oral liquid
By combining lactic acid bacteria and plant ingredients, this product addresses the shortcomings of existing oral liquids in terms of anti-inflammatory, antibacterial, and deodorizing properties, achieving safe and efficient oral care. It establishes a beneficial microbial flora, inhibits the growth of pathogenic bacteria, and neutralizes odors.
Patent Information
- Application Number
- CN202511689850.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-18
- Publication Date
- 2026-01-23
AI Technical Summary
Existing oral solutions are not very effective in reducing inflammation, inhibiting bacteria, and deodorizing. Furthermore, long-term use of chemical antibacterial agents or antibiotics poses safety concerns and fails to maintain the balance of oral microbiota.
It uses a combination of lactic acid bacteria freeze-dried powder, plant extracts and plant essential oils, including freeze-dried powders of Lactobacillus paracasei, Pediococcus pentosus, and Leuconostoc mesenteroides, extracts of Bletilla striata, Phellodendron chinense, Curcuma zedoaria, and Glycyrrhiza uralensis, as well as myrtle, Amomum villosum and Sage oil. It achieves anti-inflammatory, antibacterial and deodorizing effects by inhibiting the adhesion of pathogenic bacteria, regulating immunity and neutralizing odors.
It establishes a beneficial microbial community, inhibits the growth of pathogenic bacteria, provides significant anti-inflammatory and deodorizing effects, has high safety, and avoids the adverse reactions of chemical antibacterial agents and antibiotics.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the technical field of oral care, and particularly relates to an anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria and a preparation method. BACKGROUND
[0002] Oral liquid, as the name implies, is a liquid used in the oral cavity, and is usually referred to as oral care liquid. Oral care liquid is a liquid product for assisting in cleaning the oral cavity and maintaining oral health, and the main functions include inhibiting bacterial growth, freshening breath, preventing periodontitis and gingivitis, and the like. At present, the common oral care liquids on the market achieve the purposes of anti-inflammatory and antibacterial by adding chemical antibacterial agents such as chlorhexidine, cetylpyridinium chloride, or antibiotics. However, long-term use of products containing chemical antibacterial agents can easily destroy the microbial balance in the oral cavity, cause oral flora imbalance, make harmful bacteria in the oral cavity produce drug resistance, and also can stimulate the oral mucosa and cause adverse reactions such as allergy; and long-term use of antibiotics has the risk of inducing bacterial drug resistance. In addition, the existing oral care products mostly use the method of covering odors to achieve deodorization, and cannot fundamentally solve the problem of odor caused by bacterial metabolism.
[0003] Therefore, there is an urgent need in the market for an oral liquid that can simultaneously achieve the effects of anti-inflammatory, antibacterial and deodorization, and is safe and relatively mild. SUMMARY
[0004] The purpose of the present application is to provide an anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria and a preparation method, which solves the technical problem that the existing oral liquid cannot simultaneously achieve the effects of anti-inflammatory, antibacterial and deodorization.
[0005] The purpose of the present application can be achieved by the following technical solutions: The present application provides an anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria, which comprises the following raw materials: Lactic acid bacteria freeze-dried powder, plant extract, and plant essential oil; The lactic acid bacteria freeze-dried powder comprises Lactobacillus paracasei freeze-dried powder, Pediococcus pentosaceus freeze-dried powder, and Leuconostoc mesenteroides freeze-dried powder; The plant extract comprises Bletilla striata extract, Chinese wampee extract, Curcuma zedoary extract, and licorice extract; The plant essential oil comprises myrtle oil, cardamom oil, and sage oil.
[0006] As a preferred technical solution of the present application, the oral liquid comprises 2.4-3.5 parts by weight of lactic acid bacteria freeze-dried powder, 4-6.3 parts by weight of plant extract, and 1.1-1.7 parts by weight of plant essential oil.
[0007] As a preferred technical solution of the present application, the freeze-dried powder of lactic acid bacteria comprises 1-1.5 parts by weight of freeze-dried powder of Lactobacillus paracasei, 0.6-1 part by weight of freeze-dried powder of Pediococcus pentosaceus, and 0.8-1 part by weight of freeze-dried powder of Leuconostoc mesenteroides.
[0008] Further, the preparation methods of the freeze-dried powder of Lactobacillus paracasei, the freeze-dried powder of Pediococcus pentosaceus, and the freeze-dried powder of Leuconostoc mesenteroides are as follows: The fermentation broth raw material is subjected to controlled-speed centrifugation, and the supernatant is discarded, and the precipitate is collected. The precipitate is subjected to temperature-controlled freezing overnight and then freeze-drying, to obtain the freeze-dried powder.
[0009] Further, the speed of the controlled-speed centrifugation is 5000-7000 r / min, and the time is 5-10 min; the temperature of the temperature-controlled freezing overnight is (-70) - (-75) °C; and the time of the freeze-drying is 24-26 h.
[0010] Further, the fermentation broth raw material of the freeze-dried powder of Lactobacillus paracasei is Lactobacillus paracasei fermentation broth with an effective viable bacterial count of 1x10 7 -1x10 9 CFU / mL, the fermentation broth raw material of the freeze-dried powder of Pediococcus pentosaceus is Pediococcus pentosaceus fermentation broth with an effective viable bacterial count of 1x10 6 -1x10 8 CFU / mL, and the fermentation broth raw material of the freeze-dried powder of Leuconostoc mesenteroides is Leuconostoc mesenteroides activation liquid with an effective viable bacterial count of 1x10 6 -1x10 9 CFU / mL. Adhesion is a prerequisite for pathogenic bacteria to colonize the body and exert their effects. Lactobacillus paracasei can effectively prevent pathogenic bacteria from binding to adhesion sites, thereby hindering the adhesion of pathogenic bacteria to the surface of teeth. Pediococcus pentosaceus can produce various bacteriocins, organic acids, and other substances, which can effectively destroy the cell membranes of harmful bacteria, causing the contents of the cells to flow out and thus killing the harmful bacteria. Leuconostoc mesenteroides can effectively promote the immune regulation of the oral cavity by inhibiting Th1 response and stimulating Th2 response.
[0011] Preferably, the effective viable bacterial count of the Lactobacillus paracasei activation liquid is 1x10 9 CFU / mL, the effective viable bacterial count of the Pediococcus pentosaceus activation liquid is 1x10 7 CFU / mL, and the effective viable bacterial count of the Leuconostoc mesenteroides activation liquid is 1x10 9 CFU / mL.
[0012] Furthermore, the *Lactobacillus paracasei* activation solution, *Pediococcus pentosaceus* activation solution, and *Leuconostoc mesenteroides* activation solution are activation solutions obtained by inoculating *Lactobacillus paracasei*, *Pediococcus pentosaceus*, and *Leuconostoc mesenteroides* into commonly used culture media and culturing them using conventional methods. There are no special requirements regarding the culture media and culturing methods used, except that they differ from those known in the art. The key is to ensure that the effective viable count of *Lactobacillus paracasei* activation solution reaches 1 x 102. 7 -1x10 9 The CFU / mL range indicates that the effective viable count of *Pediococcus pentosaceus* activation solution reaches 1 x 10⁻⁶. 6 -1x10 8 The CFU / mL range indicates that the effective viable bacterial count of the Leuconostoc mesentery activation solution reaches 1x10⁻⁶. 6 -1x10 9 Any range of CFU / mL can achieve the objective of this invention.
[0013] As a preferred embodiment of the present invention, the plant extract includes 0.5-1 parts by weight of Bletilla striata extract, 2-3 parts by weight of Scutellaria baicalensis extract, 0.5-0.8 parts by weight of Curcuma zedoaria extract, and 1-1.5 parts by weight of Glycyrrhiza uralensis extract. Bletilla striata extract is rich in Bletilla striata glucomannan and Bletilla striata alcohol, which have the effects of promoting epithelial cell repair, stimulating macrophage activation, reducing swelling and promoting tissue regeneration, and can provide excellent anti-inflammatory and repairing effects. The extract of PONGAMIA PINNATA contains flavonoids and triterpenoids, and has the effects of clearing heat and detoxifying, anti-inflammatory and antibacterial properties. It can inhibit the production and release of inflammatory factors and provide certain antibacterial effects. Curcuma zedoaria extract contains components such as demethoxycurcumin, curcumin and bisdemethoxycurcumin, which have excellent inhibitory effects on nuclear factor κB receptor activation and can provide good anti-inflammatory effects. Licorice (Glycyrrhiza uralensis) extract is rich in triterpenoids and has the effects of tonifying the middle energizer and replenishing qi, relieving pain, clearing heat and detoxifying, and harmonizing various medicines. It can effectively inhibit the COX-2 / NF-κB pathway to exert anti-inflammatory effects.
[0014] As a preferred embodiment of the present invention, the plant essential oil includes 0.3-0.5 parts by weight of myrtle oil, 0.5-0.8 parts by weight of cardamom oil, and 0.3-0.4 parts by weight of sage oil.
[0015] Myrtle (MYRTUS COMMUNIS) oil has a fresh, slightly sweet aroma and has a certain antibacterial effect on bacteria that produce volatile sulfur compounds, such as Fusobacterium nucleatum and Porphyromonas gingivalis. Amomum villosa Xanthioides oil has a strong aromatic aroma and a slightly spicy taste. Its active ingredients can form bonds or complexes with odor molecules to neutralize unpleasant odors. Sage (SALVIA HISPANICA) oil has a warm and soothing scent, and its active groups, such as conjugated molecular bonds, can effectively neutralize odors and significantly reduce their concentration.
[0016] As a preferred embodiment of the present invention, the preparation methods of the myrtle oil, cardamom oil, and sage oil are all as follows: After crushing the raw material, soak it in distilled water for 0.5-1 hour, then heat it over a direct flame for 5-6 hours to extract the volatile oil. Collect the distillate, separate it, and the volatile oil is obtained.
[0017] As a preferred embodiment of the present invention, the raw material for preparing the myrtle oil is myrtle leaves, and the ratio of the myrtle leaves to distilled water is 1:6-10; the raw material for preparing the cardamom oil is cardamom seeds, and the ratio of the cardamom seeds to distilled water is 1:8-10; the raw material for preparing the sage oil is dried whole sage, and the ratio of the dried whole sage to distilled water is 1:8-10.
[0018] Preferably, the ratio of the myrtle leaves to distilled water is 1:10, the ratio of the cardamom seeds to distilled water is 1:8, and the ratio of the dried whole sage to distilled water is 1:8.
[0019] As a preferred embodiment of the present invention, the oral liquid further includes a humectant, a flavoring agent, a solubilizer, an antioxidant, and deionized water.
[0020] As a preferred embodiment of the present invention, the oral liquid comprises 5-8 parts by weight of a humectant, 1-3 parts by weight of a flavoring agent, 0.4-0.6 parts by weight of a solubilizer, 0.05-0.1 parts by weight of an antioxidant, and 80-84 parts by weight of deionized water.
[0021] As a preferred embodiment of the present invention, the moisturizer includes at least one of glycerin and sorbitol.
[0022] As a preferred embodiment of the present invention, the flavoring agent includes at least one of erythritol, xylitol, and stevioside.
[0023] As a preferred embodiment of the present invention, the solubilizer includes Tween-80.
[0024] As a preferred embodiment of the present invention, the antioxidant includes sodium citrate.
[0025] The second aspect of this application provides a method for preparing an anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria, comprising the following preparation steps: S1. Mix and stir the plant essential oil, half the weight of deionized water and solubilizer to obtain the oil phase; S2. Mix and stir the lyophilized lactic acid bacteria powder, plant extracts, humectants, flavoring agents, antioxidants and the remaining deionized water to obtain the aqueous phase; S3. While stirring, add the oil phase to the aqueous phase to obtain the oral liquid.
[0026] As a preferred embodiment of the present invention, the stirring speed in step S1 is 300-400 r / min and the time is 0.5-1 h; the stirring speed in step S2 is 300-500 r / min and the time is 15-30 min; the conditions for adding while stirring in step S3 are: adding slowly and evenly within 15-20 min at a stirring speed of 300-350 r / min.
[0027] The beneficial effects of this invention are: (1) The application of probiotics is beneficial to the establishment of beneficial microbial flora, thereby inhibiting the growth and reproduction of pathogenic microorganisms. Therefore, the present invention uses Lactobacillus paracasei, Pediococcus pentosus and Leuconostoc mesenteroides as compound lactic acid bacteria freeze-dried powder, which can effectively inhibit the adhesion of pathogenic bacteria in the oral cavity, inhibit the formation of pathogenic bacteria biofilm, and interfere with the binding of pathogenic microorganisms to the tooth surface through immune regulation mechanism, thereby giving oral fluid excellent antibacterial effect.
[0028] (2) The present invention selects Bletilla striata extract, Scutellaria baicalensis extract, Curcuma zedoaria extract and Glycyrrhiza uralensis extract, respectively from different dimensions of promoting repair, anti-inflammation and antibacterial, so that the oral liquid has outstanding anti-inflammatory effect.
[0029] (3) The present invention combines three plant oils, namely myrtle oil, cardamom oil and sage oil, to complement each other and inhibit the sulfur-producing bacteria in the oral cavity more comprehensively. At the same time, the components contained therein can more effectively neutralize and mask oral odor, thus giving the oral liquid a significant deodorizing effect. Detailed Implementation
[0030] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.
[0031] The *Lactobacillus paracasei* used in the embodiments and comparative examples of this invention were purchased from Weikaiheis (Shandong) Biotechnology Co., Ltd., and the *Lactobacillus paracasei* activation solution was obtained by inoculating *Lactobacillus paracasei* into a commonly used culture medium and culturing it using conventional methods. The Pediococcus pentosus used was purchased from Shaanxi Hana Biotechnology Co., Ltd. The activated Pediococcus pentosus solution was obtained by inoculating Pediococcus pentosus into a commonly used culture medium and culturing it using conventional methods. The Leuconostoc mesenteroides used was purchased from Shenzhen Jinfuyuan Biotechnology Co., Ltd. The Leuconostoc mesenteroides activation solution was obtained by inoculating Leuconostoc mesenteroides into a commonly used culture medium and culturing it using conventional methods. The Bletilla striata extract was purchased from Shaanxi Junhe Biotechnology Co., Ltd., the Scutellaria baicalensis extract from Gansu Yishengxiang Biotechnology Co., Ltd., the Curcuma zedoaria extract from Shandong Guante Bioengineering Co., Ltd., and the Glycyrrhiza uralensis extract from Xi'an Ruierli Bioengineering Co., Ltd.; these will not be repeated hereafter.
[0032] Preparation Example 1 The preparation method of myrtle oil includes the following steps: crushing myrtle leaves and soaking them in distilled water for 1 hour, heating them directly over a fire for 6 hours, collecting the distillate, separating it, and obtaining myrtle oil. The ratio of myrtle leaves to distilled water is 1:10; The preparation method of Amomum villosum oil includes the following steps: after crushing Amomum villosum seeds, soak them in distilled water for 0.5 h, heat directly over a flame to extract for 5.5 h, collect the distillate, separate it, and then obtain Amomum villosum oil; The ratio of Amomum villosum seeds to distilled water is 1:8; The preparation method of sage oil includes the following steps: pulverizing dried whole sage and soaking it in distilled water for 0.5 h, heating it directly over a flame for 5 h, collecting the distillate, separating it, and obtaining sage oil. The ratio of dried whole sage to distilled water is 1:8.
[0033] Example 1 An anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria, the oral liquid comprising the following raw materials: The lyophilized lactic acid bacteria powder includes 1 part by weight of Lactobacillus paracasei lyophilized powder, 0.8 parts by weight of Pediococcus pentosus lyophilized powder, and 1 part by weight of Leuconostoc mesenteroides lyophilized powder. The preparation method of the Lactobacillus paracasei lyophilized powder includes the following steps: [The following steps are described in the original text: ... 8The fermentation broth of Lactobacillus paracasei (CFU / mL) was centrifuged at 5000 r / min for 10 min. The supernatant was discarded, and the precipitate was collected. The precipitate was frozen at -70℃ overnight and then freeze-dried for 26 h to obtain Lactobacillus paracasei freeze-dried powder. The preparation method of the Pediococcus pentosaccharide lyophilized powder includes the following steps: [The following steps are described in the original text: ... 6 Centrifuge the activated solution of Pediococcus pentosacchari at 7000 r / min for 5 min, discard the supernatant, collect the precipitate, freeze the precipitate at -75℃ overnight, and then freeze-dry for 24 h to obtain Pediococcus pentosacchari freeze-dried powder. The method for preparing freeze-dried Leuconostoc mesenteroides includes the following steps: [The following text appears to be a separate, unrelated section:] ...with an effective viable bacterial count of 1x10... 8 Centrifuge the activated Leuconostoc mesenteroides solution at 6000 r / min for 7.5 min, discard the supernatant, collect the precipitate, freeze the precipitate at -73℃ overnight, and then freeze-dry for 25 h to obtain Leuconostoc mesenteroides freeze-dried powder. Plant extracts, including 0.5 parts by weight of Bletilla striata extract, 2.5 parts by weight of Scutellaria baicalensis extract, 0.65 parts by weight of Curcuma zedoaria extract, and 1.25 parts by weight of Glycyrrhiza uralensis extract; The plant essential oils include 0.5 parts by weight of myrtle oil prepared in Preparation Example 1, 0.5 parts by weight of cardamom oil prepared in Preparation Example 1, and 0.4 parts by weight of sage oil prepared in Preparation Example 1. 5 parts by weight of glycerol, 2 parts by weight of xylitol, 0.5 parts by weight of Tween-80, 0.05 parts by weight of sodium citrate, and 83.35 parts by weight of deionized water; The preparation method of the lactic acid bacteria-containing anti-inflammatory and antibacterial oral liquid includes the following preparation steps: S1. Mix the plant essential oil, half the weight of deionized water and Tween-80 and stir at 400 r / min for 1 hour to obtain the oil phase; S2. Mix the lyophilized lactic acid bacteria powder, plant extract, glycerin, xylitol, sodium citrate and the remaining deionized water and stir at 400 r / min for 15 min to obtain the aqueous phase. S3. Add the oil phase slowly and evenly to the aqueous phase while stirring at a speed of 350 r / min over 15 min to obtain the oral liquid.
[0034] Example 2 An anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria, the oral liquid comprising the following raw materials: The lyophilized lactic acid bacteria powder includes 1.5 parts by weight of Lactobacillus paracasei lyophilized powder, 0.6 parts by weight of Pediococcus pentosaceus lyophilized powder, and 0.8 parts by weight of Leuconostoc mesenteroides lyophilized powder. The preparation method of the Lactobacillus paracasei lyophilized powder includes the following steps: [The following steps are described in the original text: ... 7 The fermentation broth of Lactobacillus paracasei (CFU / mL) was centrifuged at 6000 r / min for 5 min, the supernatant was discarded, the precipitate was collected, the precipitate was frozen at -75℃ overnight and then freeze-dried for 26 h to obtain Lactobacillus paracasei freeze-dried powder. The preparation method of the Pediococcus pentosaccharide lyophilized powder includes the following steps: [The following steps are described in the original text: ... 8 Centrifuge the activated solution of Pediococcus pentosacchari at a controlled speed of 5000 r / min for 10 min, discard the supernatant, collect the precipitate, freeze the precipitate at -70℃ overnight, and then freeze-dry for 25 h to obtain Pediococcus pentosacchari freeze-dried powder. The method for preparing freeze-dried Leuconostoc mesenteroides includes the following steps: [The following text appears to be a separate, unrelated section:] ...with an effective viable bacterial count of 1x10... 6 Centrifuge the activated Leuconostoc mesenteroides solution at 7000 r / min for 5 min, discard the supernatant, collect the precipitate, freeze the precipitate at -70℃ overnight, and then freeze-dry for 24 h to obtain Leuconostoc mesenteroides freeze-dried powder. Plant extracts, including 0.75 parts by weight of Bletilla striata extract, 3 parts by weight of Scutellaria baicalensis extract, 0.5 parts by weight of Curcuma zedoaria extract, and 1.5 parts by weight of Glycyrrhiza uralensis extract; The plant essential oils include 0.4 parts by weight of myrtle oil prepared in Preparation Example 1, 0.75 parts by weight of cardamom oil prepared in Preparation Example 1, and 0.35 parts by weight of sage oil prepared in Preparation Example 1. Sorbitol 8 parts by weight, Stevioside 1 part by weight, Tween-80 0.4 parts by weight, Sodium citrate 0.1 parts by weight, Deionized water 80.35 parts by weight; The preparation method of the lactic acid bacteria-containing anti-inflammatory and antibacterial oral liquid includes the following preparation steps: S1. Mix the plant essential oil, half the weight of deionized water and Tween-80 and stir at 300 r / min for 0.5 h to obtain the oil phase; S2. Mix the lyophilized lactic acid bacteria powder, plant extract, sorbitol, steviol glycoside, sodium citrate and the remaining deionized water and stir at a controlled speed of 500 r / min for 22 min to obtain the aqueous phase. S3. Add the oil phase slowly and evenly to the aqueous phase while stirring at a speed of 300 r / min over 18 minutes to obtain the oral liquid.
[0035] Example 3 An anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria, the oral liquid comprising the following raw materials: The lyophilized lactic acid bacteria powder includes 1.2 parts by weight of Lactobacillus paracasei lyophilized powder, 1 part by weight of Pediococcus pentosus lyophilized powder, and 0.9 parts by weight of Leuconostoc mesenteroides lyophilized powder. The preparation method of the Lactobacillus paracasei lyophilized powder includes the following steps: [The following steps are described in the original text: ... 9 The fermentation broth of Lactobacillus paracasei (CFU / mL) was centrifuged at 5000 r / min for 7.5 min. The supernatant was discarded, and the precipitate was collected. The precipitate was frozen at -72℃ overnight and then freeze-dried for 25 h to obtain Lactobacillus paracasei freeze-dried powder. The preparation method of the Pediococcus pentosaccharide lyophilized powder includes the following steps: [The following steps are described in the original text: ... 7 Centrifuge the activated solution of Pediococcus pentosacchari at 6000 r / min for 5 min, discard the supernatant, collect the precipitate, freeze the precipitate at -75℃ overnight, and then freeze-dry for 24 h to obtain Pediococcus pentosacchari freeze-dried powder. The method for preparing freeze-dried Leuconostoc mesenteroides includes the following steps: [The following text appears to be a separate, unrelated section:] ...with an effective viable bacterial count of 1x10... 9 Centrifuge the activated Leuconostoc mesenteroides solution at 6000 r / min for 10 min, discard the supernatant, collect the precipitate, freeze the precipitate at -73℃ overnight, and then freeze-dry for 26 h to obtain Leuconostoc mesenteroides freeze-dried powder. Plant extracts, including 1 part by weight of Bletilla striata extract, 2 parts by weight of Scutellaria baicalensis extract, 0.8 parts by weight of Curcuma zedoaria extract, and 1 part by weight of Glycyrrhiza uralensis extract; The plant essential oils include 0.3 parts by weight of myrtle oil prepared in Preparation Example 1, 0.8 parts by weight of cardamom oil prepared in Preparation Example 1, and 0.3 parts by weight of sage oil prepared in Preparation Example 1. Sorbitol 6.5 parts by weight, erythritol 3 parts by weight, Tween-80 0.6 parts by weight, sodium citrate 0.07 parts by weight, deionized water 80.53 parts by weight; The preparation method of the lactic acid bacteria-containing anti-inflammatory and antibacterial oral liquid includes the following preparation steps: S1. Mix the plant essential oil, half the weight of deionized water and Tween-80 and stir at 350 r / min for 1 hour to obtain the oil phase; S2. Mix the lyophilized lactic acid bacteria powder, plant extract, sorbitol, erythritol, sodium citrate and the remaining deionized water and stir at 300 r / min for 30 min to obtain the aqueous phase. S3. Add the oil phase slowly and evenly to the aqueous phase while stirring at a speed of 325 r / min over 20 min to obtain the oral liquid.
[0036] Comparative Example 1 The difference between Comparative Example 1 and Example 3 is that no Lactobacillus paracasei activation solution was added, i.e., in Comparative Example 1: Lactic acid bacteria freeze-dried powder contains 1x10 effective live bacteria. 71.6 parts by weight of Pediococcus pentosaceus activation solution with CFU / mL, effective viable count of 1 x 10⁻⁶ cells / mL. 9 1.5 parts by weight of CFU / mL Leuconostoc mesenteroides activation solution; all other contents remained unchanged.
[0037] Comparative Example 2 The difference between Comparative Example 2 and Example 3 is that Pediococcus pentosaceus activation solution was not added, i.e., in Comparative Example 1: Lactic acid bacteria freeze-dried powder contains 1x10 effective live bacteria. 9 1.7 parts by weight of Lactobacillus paracasei activation solution with CFU / mL, effective viable count of 1 x 102 9 1.4 parts by weight of CFU / mL Leuconostoc mesenteroides activation solution; all other contents remained unchanged.
[0038] Comparative Example 3 The difference between Comparative Example 3 and Example 3 is that Leuconostoc mesenteroides activation solution was not added, i.e., in Comparative Example 1: The lyophilized lactic acid bacteria powder contains 1 x 10^9 effective live bacteria. 9 1.65 parts by weight of Lactobacillus paracasei activation solution with CFU / mL, effective viable count of 1 x 10⁻⁶. 7 1.45 parts by weight of activated Pediococcus pentosaceus solution with CFU / mL; all other parameters remained unchanged.
[0039] Test Example 1 According to section 7.3.3 of standard QB / T 2738-2012, Staphylococcus aureus ATCC 6538, Escherichia coli 8099, and Candida albicans ATCC 10231 were used as test strains. The contact time was 2 min. The antibacterial effects of the oral liquids prepared in Examples 1-3 and Comparative Examples 1-3 were tested respectively, and the results are shown in Table 1.
[0040] Table 1 As can be seen from Table 1, the oral liquid prepared by this invention has excellent antibacterial effect.
[0041] Comparative Example 4 The difference between Comparative Example 4 and Example 3 is that Bletilla striata extract was not added. That is, the plant extracts included: 2.3 parts by weight of Scutellaria baicalensis extract, 1.2 parts by weight of Curcuma zedoaria extract, and 1.3 parts by weight of Glycyrrhiza uralensis extract; the rest remained unchanged.
[0042] Comparative Example 5 The difference between Comparative Example 5 and Example 3 is that no yellow peel extract was added. That is, the plant extracts include: 1.6 parts by weight of Bletilla striata extract, 1.5 parts by weight of Curcuma zedoaria extract, and 1.7 parts by weight of Glycyrrhiza uralensis extract; all other parts remain unchanged.
[0043] Comparative Example 6 The difference between Comparative Example 6 and Example 3 is that Curcuma zedoaria extract is not added. That is, the plant extracts include: 1.3 parts by weight of Bletilla striata extract, 2.2 parts by weight of Phellodendron chinense extract, and 1.3 parts by weight of Glycyrrhiza uralensis extract; the rest remain unchanged.
[0044] Comparative Example 7 The difference between Comparative Example 7 and Example 3 is that licorice extract is not added. That is, the plant extracts include: 1.3 parts by weight of Bletilla striata extract, 2.3 parts by weight of Scutellaria baicalensis extract, and 1.2 parts by weight of Curcuma zedoaria extract; all other components remain unchanged.
[0045] Test Example 2 Volunteers aged 25-45 with different disease courses of gingivitis and periodontitis were invited, regardless of gender, and randomly divided into 7 groups of 12 people each. After routine supragingival scaling, each group of volunteers used the oral liquid prepared in Examples 1-3 and Comparative Examples 4-7 to rinse for 45 seconds, once each in the morning, noon and evening, 20ml each time, for one month.
[0046] The evaluation criteria for antibacterial and anti-inflammatory effects are as follows: Cured: Gingivitis and periodontitis are completely cured; Effective: Gingivitis and periodontitis show significant improvement; Ineffective: Gingivitis and periodontitis show no improvement or worsen.
[0047] The results are shown in Table 2.
[0048] Table 2 As can be seen from Table 2, the oral liquid prepared by this invention has outstanding anti-inflammatory effects.
[0049] Comparative Example 8 The difference between Comparative Example 8 and Example 3 is that myrtle oil is not added; that is, the plant essential oil includes 0.95 parts by weight of cardamom oil prepared in Example 1 and 0.45 parts by weight of sage oil prepared in Example 1; all other parts remain the same.
[0050] Comparative Example 9 The difference between Comparative Example 9 and Example 3 is that no cardamom oil was added. That is, the plant essential oils included 0.7 parts by weight of myrtle oil prepared in Example 1 and 0.7 parts by weight of sage oil prepared in Example 1; all other parts remained the same.
[0051] Comparative Example 10 The difference between Comparative Example 10 and Example 3 is that sage oil is not added; that is, the plant essential oil includes 0.45 parts by weight of myrtle oil prepared in Example 1 and 0.95 parts by weight of cardamom oil prepared in Example 1; all other parts remain the same.
[0052] Test Example 3 Volunteers aged 25-45 without dental caries, regardless of gender, were randomly divided into 6 groups of 12 each. Commercially available garlic powder was dispersed in water and left to stand for 24 hours, then diluted to a reading of 500 ppb or higher using a breathalyzer. This diluted solution was used as a halitosis inducing agent. Each group of volunteers rinsed their mouths with 20 ml of the diluted garlic powder solution for 30 seconds. One minute later, the degree of halitosis was measured using a breathalyzer to ensure a reading between 500-520 ppb. Then, each group of volunteers rinsed their mouths for 60 seconds using oral solutions prepared in Examples 1-3 and Comparative Examples 8-10. After rinsing, a 5-minute wait was followed by a breathalyzer reading to assess the effectiveness of the oral solution. The evaluation criteria were: a breathalyzer reading ≥110 ppb after 5 minutes of rinsing indicated the oral solution was ineffective; otherwise, it was effective.
[0053] The results are shown in Table 3.
[0054] Table 3 As can be seen from Table 3, the oral liquid prepared by this invention has a significant deodorizing effect.
[0055] In the description of this specification, the references to terms such as "an embodiment," "example," "specific example," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples.
[0056] The above description is merely an example and illustration of the concept of the present invention. Those skilled in the art can make various modifications or additions to the specific embodiments described or use similar methods to replace them, as long as they do not deviate from the concept of the invention or exceed the scope defined in the claims, they should all fall within the protection scope of the present invention.
Claims
1. An anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria, characterized in that, The oral fluid comprises the following ingredients: Lactic acid bacteria freeze-dried powder, plant extracts, plant essential oils; The lactic acid bacteria freeze-dried powder includes Lactobacillus paracasei freeze-dried powder, Pediococcus pentosacchari freeze-dried powder, and Leuconostoc mesenteroides freeze-dried powder. The plant extracts include Bletilla striata extract, Cinnamomum cassia extract, Curcuma zedoaria extract, and Glycyrrhiza uralensis extract; The plant essential oils include myrtle oil, cardamom oil, and sage oil.
2. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 1, characterized in that, It includes 2.4-3.5 parts by weight of lyophilized lactic acid bacteria powder, 4-6.3 parts by weight of plant extracts, and 1.1-1.7 parts by weight of plant essential oils.
3. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 2, characterized in that, It includes 1-1.5 parts by weight of Lactobacillus paracasei lyophilized powder, 0.6-1 parts by weight of Pediococcus pentosus lyophilized powder, and 0.8-1 parts by weight of Leuconostoc mesenteroides lyophilized powder.
4. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 2, characterized in that, It includes 0.5-1 parts by weight of Bletilla striata extract, 2-3 parts by weight of Scutellaria baicalensis extract, 0.5-0.8 parts by weight of Curcuma zedoaria extract, and 1-1.5 parts by weight of Glycyrrhiza uralensis extract.
5. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 2, characterized in that, It includes 0.3-0.5 parts by weight of myrtle oil, 0.5-0.8 parts by weight of cardamom oil, and 0.3-0.4 parts by weight of sage oil.
6. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 2, characterized in that, The lyophilized powder of Lactobacillus paracasei includes 1.2 parts by weight, the lyophilized powder of Pediococcus pentosaceus includes 1 part by weight, and the lyophilized powder of Leuconostoc mesenteroides includes 0.9 parts by weight; the extract of Bletilla striata includes 1 part by weight, the extract of Phellodendron chinense includes 2 parts by weight, the extract of Curcuma zedoaria includes 0.8 parts by weight, and the extract of Glycyrrhiza uralensis includes 1 part by weight; the extract of Myristica fragrans includes 0.3 parts by weight, the extract of Amomum villosum includes 0.8 parts by weight, and the extract of Sage includes 0.3 parts by weight.
7. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 1, characterized in that, It includes 5-8 parts by weight of humectant, 1-3 parts by weight of flavoring agent, 0.4-0.6 parts by weight of solubilizer, 0.05-0.1 parts by weight of antioxidant, and 80-84 parts by weight of deionized water.
8. The anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 5, characterized in that, The humectant includes at least one of glycerin and sorbitol; the flavoring agent includes at least one of erythritol, xylitol, and steviol; the solubilizer includes Tween-80; and the antioxidant includes sodium citrate.
9. A method for preparing an anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria as described in any one of claims 1-8, characterized in that, The preparation steps include the following: S1. Mix and stir the plant essential oil, half the weight of deionized water and solubilizer to obtain the oil phase; S2. Mix and stir the lyophilized lactic acid bacteria powder, plant extracts, humectants, flavoring agents, antioxidants and the remaining deionized water to obtain the aqueous phase; S3. While stirring, add the oil phase to the aqueous phase to obtain the oral liquid.
10. The method for preparing the anti-inflammatory and antibacterial oral liquid containing lactic acid bacteria according to claim 9, characterized in that, In step S1, the stirring speed is 300-400 r / min and the time is 0.5-1 h; in step S2, the stirring speed is 300-500 r / min and the time is 15-30 min; in step S3, the condition for adding while stirring is: adding slowly and evenly over 15-20 min at a stirring speed of 300-350 r / min.